Methyldopa Cf (Methyldopa)

After oral absorption, methyldopa is converted to alpha‑methyldopamine. This metabolite stimulates central alpha‑2 adrenergic receptors in the brainstem, reducing sympathetic nervous system outflow. The resulting decrease in peripheral vascular resistance and modest reduction in heart rate leads to lower systemic blood pressure.

The appropriate dose of Methyldopa Cf is individualized by the prescribing healthcare professional based on factors such as the severity of hypertension, patient age, renal function, and response to therapy. Dosage adjustments are made according to clinical monitoring rather than a fixed regimen.

Methyldopa has historically been used to treat hypertension in pregnancy because it does not appear to cause fetal harm in available studies. However, safety data are limited, and the decision to use it during pregnancy or while breastfeeding should be made by a qualified clinician after weighing potential benefits and risks.

To request Methyldopa Cf, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, and will ask for trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Methyldopa is a centrally acting alpha‑2 agonist, whereas many other antihypertensives act peripherally (e.g., ACE inhibitors, calcium‑channel blockers). It is often chosen for its safety profile in pregnancy and for patients who may not tolerate diuretics or beta‑blockers, but it may cause more central nervous system side effects such as drowsiness.

Methyldopa Cf should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain its stability and potency throughout its shelf life.

Methyldopa Cf is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional. Dosing frequency and timing are determined by the prescriber based on individual therapeutic goals.

Serious adverse events, although uncommon, include severe hypotension, liver injury, hemolytic anemia, agranulocytosis, and severe skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience symptoms like jaundice, unexplained fatigue, rash, or a sudden drop in blood pressure.

Methyldopa Cf is contraindicated in individuals with known hypersensitivity to methyldopa or any of its excipients. Caution is advised for patients with severe liver disease, active depression, or a history of blood dyscrasias. It should also be avoided in patients taking monoamine oxidase inhibitors due to the risk of hypertensive crisis.